The company is an early-stage biotech that aims to improve mental health by developing drugs that treat neuropsychiatric conditions such as depression, anxiety, substance use, and stress-related disorders. Gilgamesh's compounds build upon the benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Mental health is a pressing global issue, and Gilgamesh seeks to accelerate treatments and fundamentally improve mental health by providing patients with new and effective treatments for their conditions.